托伐普坦治疗常染色体显性多囊肾病中排水相关症状的耐受性:TEMPO 3:4 结果
该研究为 TEMPO 3:4 随机对照试验及其开放标签扩展 TEMPO 4:4 的事后分析,评估托伐普坦治疗 ADPKD 时排水相关不良事件(AAE)导致的停药情况。结果显示 78% 的托伐普坦治疗者报告至少一种 AAE,其中 10% 因 AAE 停药,停药者更年轻、基线肾功能更好、空腹尿渗透压更高;治疗 3 年后 75% 托伐普坦组和 85% 安慰剂组表示可终身耐受当前剂量。
要点
- ADPKD 患者使用托伐普坦时排水相关不良事件常见但总体耐受良好。
- 因排水症状停药者更年轻、基线肾功能更好、空腹尿渗透压更高。
- 治疗 3 年后 75% 托伐普坦组和 85% 安慰剂组表示可终身耐受当前剂量。
核心结论
- 在 ADPKD 患者中,托伐普坦相关排水不良事件常见但耐受性良好。
- 疾病进展较早阶段的患者可能对排水症状更敏感,有助于指导托伐普坦剂量和滴定决策。
研究设计与样本
- TEMPO 3:4 随机安慰剂对照试验及其开放标签扩展 TEMPO 4:4 的事后分析。
- TEMPO 3:4 中 961 例接受托伐普坦治疗,其中 750 例(78%)报告至少一种排水相关不良事件。
主要发现
- 750 例报告 AAE 的患者中,72 例(10%)因 AAE 停药,573 例(76%)继续治疗,105 例(14%)因其他原因停药。
- 因 AAE 停药者相比继续治疗者更年轻、基线肾功能更好、空腹尿渗透压更高。
- 相比非 AAE 停药者,因 AAE 停药者更多为男性、基线肾功能更好、停药更快。
- 治疗 3 年后,75% 托伐普坦组和 85% 安慰剂组表示可终身耐受当前剂量。
- TEMPO 4:4 开放标签扩展试验结果与上述发现一致。
临床怎么用
- 临床中应关注 ADPKD 患者托伐普坦治疗时的排水相关症状,但多数患者可耐受。
- 对较早疾病阶段的患者,排水症状可能更明显,需个体化调整剂量和滴定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD). Consistent with its primary pharmacologic activity, tolvaptan use was commonly associated with aquaretic adverse events (AAEs) attributable to excess free water clearance. METHODS: A post hoc analysis of tolvaptan-related discontinuations from the pivotal randomized controlled trial TEMPO 3:4 and its open-label extension TEMPO 4:4. RESULTS: In total, 750 of 961 tolvaptan-treated subjects (78%) in TEMPO 3:4 reported at least one AAE. Of these 750 subjects, 72 (10%) discontinued because of an AAE (aquaretic-discontinued group) and 573 (76%) continued (aquaretic-continued group). The aquaretic-discontinued subjects were younger, had better baseline renal function, and had higher fasting urine osmolality than aquaretic-continued subjects. Of the 750 subjects reporting an AAE, 105 (14%) discontinued for another reason (non-aquaretic-discontinued group). Compared to non-aquaretic-discontinued subjects, aquaretic-discontinued subjects were more commonly male, had better baseline renal function, and discontinued the study drug faster. After 3 years of therapy, 75% of tolvaptan subjects indicated that they could tolerate their current dose for the rest of their lives, compared to 85% of placebo subjects. These findings were corroborated by results in the open-label extension trial TEMPO 4:4. DISCUSSION: In this study, AAEs were common but well tolerated in ADPKD patients on tolvaptan. ADPKD patients in earlier stages of disease progression may be more sensitive to aquaretic symptoms, which may help in guiding tolvaptan dosing and titration decisions in the future.
引用
- Devuyst O, Chapman AB, Shoaf SE, et al. Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. Kidney Int Rep. 2017. PMID: 29270521. doi:10.1016/j.ekir.2017.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。